Ligand News and Research

RSS

New strategy combines cancer immunotherapy and gene therapy in a single nanoparticle

Cancer cells survive by hiding from the immune system's surveillance. A KAIST research team has developed a new anticancer platform that makes cancer cells send out their own danger signal—prompting immune cells to attack—while simultaneously delivering gene therapy.

28 Jul 2026

Thymulin curbs age-related inflammation and slows breast tumors in mice

Thymulin reduced age-associated inflammatory myeloid cells and slowed breast-tumor growth in aged mice by suppressing NF-κB signaling. The peptide also restored anti-PD-L1 responsiveness in aged mouse models, while human cell and tumor data supported an age-linked inflammatory myeloid profile.

23 Jul 2026

New EV-SELEX strategy accelerates drug discovery for wide range of GPCRs

G protein-coupled receptors (GPCRs) are the most abundantly expressed proteins in the human body, which regulate diverse physiological processes ranging from pain perception to hormone signaling.

7 Jul 2026

New spatially resolved transcriptomic map reveals how bone and muscle cells communicate

A new study generated one of the most comprehensive spatially resolved transcriptomic maps of cellular communication between bone and skeletal muscle in a young mouse.

6 Jul 2026

Feeder-free TIL expansion system makes advanced cancer immunotherapy safer

Conventional TIL therapy, clinically validatedrecently with the U.S. Food and Drug Administration approval of lifileucel for advanced melanoma,stillfaces substantial hurdles.

3 Jul 2026

Reversing macrophage metabolism may improve cancer immunotherapy outcomes

Tumor-associated macrophages (TAMs) are among the most abundant immune cells in the tumor microenvironment.

1 Jul 2026

Altering gut microbes could improve immunotherapy responses in liver cancer

Immune checkpoint blockade (ICB) has reshaped the treatment landscape for advanced hepatocellular carcinoma (HCC), offering new hope where few options existed.

30 Jun 2026

Melatonin dampens fetal membrane inflammation linked to preterm birth

Melatonin reduced infection-related inflammation in human fetal membranes in an ex vivo model. The study suggests that this effect works partly through melatonin receptors and by suppressing the TLR4/MyD88/NF-κB pathway.

28 Jun 2026

Scientists uncover immune mechanisms driving rare gastrointestinal disorder

A collaborative team led by Dr. Jingnan Li and Dr. Ji Li at Peking Union Medical College Hospital, together with Associate Professor Xiaohuan Guo at Tsinghua University and Academician Ye-Guang Chen at Tsinghua University School of Life Sciences, published a study in Volume 2, article number 28 of the journal Immunity & Inflammation on June 17, 2026.

26 Jun 2026

Cone opsin structures offer insights into vision loss

The retina of the human eye contains six to seven million cone cells. These cells contain light-sensitive proteins known as cone opsins.

25 Jun 2026

Researchers develop novel strategy to selectively target tumor microenvironments

A new collaborative study reports the discovery and application of a novel therapeutic strategy to selectively target EGFR and other kinases with controlled release in tumor microenvironments to improve therapeutic efficacy, with promising results.

25 Jun 2026

Sugar-coated nanoparticles extend survival in aggressive glioblastoma mouse model

Researchers at Oregon State University have potentially found a new way to treat the most aggressive form of brain cancer, glioblastoma, whose two-year survival rate is less than 30%.

23 Jun 2026

Skin barrier monitoring predicts necrosis after skin flap surgery

Random-pattern skin flaps (RPSFs) receive blood mainly from small subcutaneous vessels rather than a defined axial vessel, leaving them vulnerable to ischemia and hypoxia after surgery.

23 Jun 2026

New vascularized grafts may improve bladder surgery for children

Can growing blood vessels within a lab-engineered graft improve bladder reconstruction for children? For more than two decades, UC Davis pediatric urologic surgeon Eric Kurzrock has been developing and testing grafts to avoid the complications after standard enterocystoplasty, a surgery for bladder augmentation.

12 Jun 2026

Automated self-driving labs accelerate the search for new medicines

The Acceleration Consortium (AC) at the University of Toronto and the Structural Genomics Consortium (SGC) announced today a formalized partnership to help tackle a persistent challenge in biomedicine and early drug discovery: the development of bioactive molecules with drug-like properties, advancing our understanding of human health and disease and jump-starting new drug discovery programs.

10 Jun 2026

New study frames altered protein modifications as cancer drivers

Cancer has often been explained through mutations in deoxyribonucleic acid (DNA) or changes in ribonucleic acid (RNA), but these layers do not fully explain why tumors with similar genetic profiles can behave differently.

9 Jun 2026

How Programmable Nanobiology Could Drive the Fifth Industrial Revolution

Professor Heddle's insights on nanobiology and AI highlight their potential to innovate drug delivery and vaccine development, addressing critical health needs.

9 Jun 2026

Novel therapeutic agent proposed to combat drug resistant tuberculosis

A research team led by Associate Professor Noriyuki Kurita from the Department of Computer Science and Engineering at Toyohashi University of Technology and by Associate Professor Pornpan Pungpo from Ubon Ratchathani University in Thailand has proposed a novel therapeutic agent for tuberculosis, using high-precision molecular simulation techniques.

29 May 2026

New X-ray system produces high-resolution images with less radiation

X-rays allow professionals to diagnose injuries or ailments and peer inside suitcases at the airport, along with a variety of other applications.

27 May 2026

One-time gene editing cuts LDL cholesterol in early hypercholesterolemia trial

A phase 1 NEJM interim analysis found that a single infusion of the investigational base-editing therapy VERVE-102 produced dose-dependent reductions in circulating PCSK9 protein and LDL cholesterol in adults with heterozygous familial hypercholesterolemia or premature coronary artery disease.

26 May 2026